Tina-quant® HbA1c - Setting a new precedent in HbA1c lab efficiency
Diabetes mellitus, ranking 7th in the top ten global causes of death, has become a worldwide health topic.1 In 2017, 1 in every 11 adults was diagnosed with diabetes (425 million) with as many as half of those undiagnosed.2
HbA1c, which reflects the average glucose level in the last 8-12 weeks, is one of the most widely used tests in diabetes management. Current ADA guidelines recommend the HbA1c tests for use in diagnosing type 2 diabetes and prediabetes.2,3 Therefore, it is critical for the lab to use a standardised assay with good quality to support the right clinical decision.
On cobas® series platforms, the Tina-quant® HbA1c assay empowers the laboratory to reduce TAT, optimise operational cost with various solutions, and build confidence on the results for clinical decisions.